Skip Navigation LinksHome > December 2010 - Volume 33 - Issue 6 > Phase II Study of Docetaxel and Cisplatin Chemotherapy in 5-...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e3181bead92
Original Article: Thoracic

Phase II Study of Docetaxel and Cisplatin Chemotherapy in 5-Fluorouracil/Cisplatin Pretreated Esophageal Cancer

Shim, Hyun-Jeong MD, PhD*; Cho, Sang-Hee MD, PhD*; Hwang, Jun-Eul MD*; Bae, Woo-Kyun MD*; Song, Sang-Yun MD†; Cho, Sung-Bum MD, PhD*; Lee, Wan-Sik MD, PhD*; Joo, Young-Eun MD, PhD*; Na, Kook-Joo MD, PhD†; Chung, Ik-Joo MD, PhD*‡

Collapse Box


Background: This study was performed to determine the feasibility and safety of salvage chemotherapy, using docetaxel and cisplatin in 5-fluorouracil (5-FU) and cisplatin-pretreated esophageal cancer.

Methods: Patients with metastatic or recurrent esophageal squamous cell carcinoma that had previously been treated with 5-FU and cisplatin chemotherapy or chemoradiotherapy were eligible for this study. Docetaxel (70 mg/m2) and cisplatin (75 mg/m2) were given as a 1-hour intravenous infusion on day 1, and the treatment was repeated every 3 weeks.

Results: Thirty-eight male patients were enrolled, and 35 patients were available for evaluation. The median age was 64.5 years; Eastern Cooperative Oncology Group performance status was 0/1/2 = 2/18/18. The median and total numbers of cycles delivered were 3.5 (range, 1–9 cycles) and 162, respectively. One patient (2.6%) achieved complete response, 12 (31.6%) achieved partial response, 12 (31.6%) had stable disease, and 10 (26.3%) had progressive disease. The overall response rate was 34.2% (95% confidence interval, 19.6–51.3). The median progression-free survival and overall survival times were 4.5 ± 1.3 months (95% CI, 4.1–4.9) and 7.4 ± 0.4 months (95% CI, 7.3–7.5), respectively. The main hematological toxicities greater than grade 3 were neutropenia and leucopenia in 20 (52.6%) and 18 patients (47.3%), respectively. Nonhematological toxicities greater than grade 3 included asthenia in 12 patients (31.6%), nausea in 7 patients (18.4%), and peripheral neuropathy in 6 patients (15.8%).

Conclusions: Chemotherapy with docetaxel and cisplatin was an effective and feasible treatment following treatment with 5-FU and cisplatin, and would be considered as a salvage option for patients with refractory esophageal cancer.

© 2010 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.